Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

R. Houston Thompson; James P. Allison; Eugene D. Kwon

doi:10.1016/j.urolonc.2005.08.011

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

R. Houston Thompson, James P. Allison, Eugene D. Kwon

Urology

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.

Original language	English (US)
Pages (from-to)	442-447
Number of pages	6
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	24
Issue number	5
DOIs	https://doi.org/10.1016/j.urolonc.2005.08.011
State	Published - Sep 2006

Keywords

CTLA-4
Costimulation
Immunotherapy
Prostatic neoplasms
T-lymphocyte

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2005.08.011

Cite this

@article{4ce82c377f5a43bdb886655b0ed0466d,

title = "Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer",

abstract = "Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.",

keywords = "CTLA-4, Costimulation, Immunotherapy, Prostatic neoplasms, T-lymphocyte",

author = "Thompson, {R. Houston} and Allison, {James P.} and Kwon, {Eugene D.}",

year = "2006",

month = sep,

doi = "10.1016/j.urolonc.2005.08.011",

language = "English (US)",

volume = "24",

pages = "442--447",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

AU - Thompson, R. Houston

AU - Allison, James P.

AU - Kwon, Eugene D.

PY - 2006/9

Y1 - 2006/9

N2 - Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.

AB - Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer.

KW - CTLA-4

KW - Costimulation

KW - Immunotherapy

KW - Prostatic neoplasms

KW - T-lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=33748171465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748171465&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.08.011

DO - 10.1016/j.urolonc.2005.08.011

M3 - Review article

C2 - 16962497

AN - SCOPUS:33748171465

SN - 1078-1439

VL - 24

SP - 442

EP - 447

JO - Urologic Oncology

JF - Urologic Oncology

IS - 5

ER -

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this